



**CoreMed Corporation**  
Tsunenari Bldg. 2-1-21 Kitahama,  
Chuo-ku, Osaka 541-0041, Japan  
TEL +81 6 6221 1352  
FAX +81 6 6221 1357

April 2026

Subject: Leadership Transition at CoreMed Corporation

Dear Valued Partners,

We would like to inform you of a leadership transition at CoreMed Corporation, effective April 1, 2026.

I am honored to assume the role of President and CEO of CoreMed Corporation as of April 1, 2026.

Over nearly three decades, CoreMed has built a strong reputation and deep trust with global partners under the leadership of Ms. Tamura. I fully recognize the responsibility of carrying this legacy forward.

Together with our highly experienced team, and with continued guidance from Ms. Tamura as Senior Advisor, we will further strengthen our expertise in Japanese regulatory and drug development strategy.

At the same time, we are committed to helping our partners navigate the complexities of the Japanese market and to accelerating patient access in Japan to innovative therapies and medical devices developed globally.

We look forward to continuing and expanding our collaboration with you.

Sincerely,  
Hitoshi Kamiya  
President and CEO  
CoreMed Corporation